

Jyh-Ming Liou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6197770/publications.pdf>

Version: 2024-02-01

110
papers

3,854
citations

126708

33
h-index

143772

57
g-index

110
all docs

110
docs citations

110
times ranked

4200
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 129. | 3.1 | 283 |
| 2 | Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensus. <i>Gut</i> , 2020, 69, 2093-2112. | 6.1 | 239 |
| 3 | Primary antibiotic resistance in <i>Helicobacter pylori</i> in the Asia-Pacific region: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 707-715. | 3.7 | 238 |
| 4 | Sequential versus triple therapy for the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. <i>Lancet</i> , The, 2013, 381, 205-213. | 6.3 | 233 |
| 5 | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. <i>Lancet</i> , The, 2016, 388, 2355-2365. | 6.3 | 128 |
| 6 | Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after <i>Helicobacter pylori</i> eradication: a multicentre, open-label, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1109-1120. | 4.6 | 127 |
| 7 | Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for <i>Helicobacter pylori</i> infection: a randomised comparative trial with crossover design. <i>Gut</i> , 2010, 59, 572-578. | 6.1 | 100 |
| 8 | Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. <i>Neurology</i> , 2022, 98, . | 1.5 | 90 |
| 9 | Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory <i>Helicobacter pylori</i> infection: a multicentre clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 450-456. | 1.3 | 82 |
| 10 | The interplay between <i>Helicobacter pylori</i> and gastrointestinal microbiota. <i>Gut Microbes</i> , 2021, 13, 1-22. | 4.3 | 79 |
| 11 | The Primary Resistance of <i>Helicobacter pylori</i> in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study. <i>PLoS ONE</i> , 2015, 10, e0124199. | 1.1 | 74 |
| 12 | Plasma Insulin-Like Growth Factor-Binding Protein-2 Levels as Diagnostic and Prognostic Biomarker of Colorectal Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1717-1725. | 1.8 | 71 |
| 13 | Sequential therapy for 10...days versus triple therapy for 14...days in the eradication of <i>Helicobacter pylori</i> in the community and hospital populations: a randomised trial. <i>Gut</i> , 2016, 65, 1784-1792. | 6.1 | 71 |
| 14 | Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201. | 1.9 | 67 |
| 15 | Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2018, 155, 1109-1119. | 0.6 | 66 |
| 16 | First-line <i>Helicobacter pylori</i> eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. <i>Gut</i> , 2018, 67, 20-27. | 6.1 | 65 |
| 17 | Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria. <i>Gut</i> , 2015, 64, 1517-1528. | 6.1 | 64 |
| 18 | Consensus on the clinical management, screening, treat, and surveillance of <i>Helicobacter pylori</i> infection to improve gastric cancer control on a nationwide scale. <i>Helicobacter</i> , 2017, 22, e12368. | 1.6 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Delayed endoscopy as a risk factor for in-hospital mortality in cirrhotic patients with acute variceal hemorrhage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1294-1299. | 1.4 | 63 |
| 20 | Genotypic Resistance in <i>Helicobacter pylori</i> Strains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1123-1129. | 1.4 | 61 |
| 21 | Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 427-437. | 1.9 | 57 |
| 22 | Primer for Development of Guidelines for <i>Helicobacter pylori</i> Therapy Using Antimicrobial Stewardship. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 973-983.e1. | 2.4 | 53 |
| 23 | Measurement of Visceral Fat: Should We Include Retroperitoneal Fat?. <i>PLoS ONE</i> , 2014, 9, e112355. | 1.1 | 52 |
| 24 | Mass Eradication of <i>Helicobacter pylori</i> to Prevent Gastric Cancer: Theoretical and Practical Considerations. <i>Gut and Liver</i> , 2016, 10, 12. | 1.4 | 51 |
| 25 | Psychopathology and Personality Trait in Subgroups of Functional Dyspepsia Based on Rome III Criteria. <i>American Journal of Gastroenterology</i> , 2009, 104, 2534-2542. | 0.2 | 50 |
| 26 | Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for <i>Helicobacter pylori</i> infection: a multicentre clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1847-1852. | 1.3 | 46 |
| 27 | Statins and the risk of pancreatic cancer in Type 2 diabetic patients—a population-based cohort study. <i>International Journal of Cancer</i> , 2016, 138, 594-603. | 2.3 | 45 |
| 28 | The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 819-825. | 0.5 | 44 |
| 29 | Evidence-based recommendations for successful <i>Helicobacter pylori</i> treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 21-28. | 1.4 | 43 |
| 30 | Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of <i>Helicobacter pylori</i> : A Randomized Trial. <i>American Journal of Gastroenterology</i> , 2016, 111, 381-387. | 0.2 | 43 |
| 31 | Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1387-1395. | 1.0 | 41 |
| 32 | Review: Treatment of <i>Helicobacter pylori</i> Infection 2019. <i>Helicobacter</i> , 2019, 24, e12640. | 1.6 | 38 |
| 33 | Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups?. <i>Journal of Gastroenterology</i> , 2011, 46, 183-190. | 2.3 | 37 |
| 34 | Efficacy and Long-Term Safety of <i>H. pylori</i> Eradication for Gastric Cancer Prevention. <i>Cancers</i> , 2019, 11, 593. | 1.7 | 36 |
| 35 | Distinct Clinicopathological Features and Prognosis of <i>Helicobacter pylori</i> Negative Gastric Cancer. <i>PLoS ONE</i> , 2017, 12, e0170942. | 1.1 | 33 |
| 36 | Transcatheter Arterial Embolization with N-Butyl Cyanoacrylate for Nonvariceal Upper Gastrointestinal Bleeding in Hemodynamically Unstable Patients: Results and Predictors of Clinical Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1850-1857. | 0.2 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The Serial Changes of Ghrelin and Leptin Levels and Their Relations to Weight Loss After Laparoscopic Minigastric Bypass Surgery. <i>Obesity Surgery</i> , 2008, 18, 84-89. | 1.1 | 30 |
| 38 | The Gut Metabolite Trimethylamine N-oxide Is Associated With Parkinson's Disease Severity and Progression. <i>Movement Disorders</i> , 2020, 35, 2115-2116. | 2.2 | 30 |
| 39 | Performance of a one-step fecal sample-based test for diagnosis of <i>Helicobacter pylori</i> infection in primary care and mass screening settings. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 899-907. | 0.8 | 29 |
| 40 | Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against <i>Helicobacter pylori</i> isolates in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 72-79. | 1.5 | 29 |
| 41 | Toward population specific and personalized treatment of <i>Helicobacter pylori</i> infection. <i>Journal of Biomedical Science</i> , 2018, 25, 70. | 2.6 | 28 |
| 42 | Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of <i>Helicobacter pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2018, 113, 1444-1457. | 0.2 | 28 |
| 43 | Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line <i>Helicobacter pylori</i> eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 59-67. | 1.4 | 26 |
| 44 | Accuracy of faecal occult blood test and <i>Helicobacter pylori</i> stool antigen test for detection of upper gastrointestinal lesions. <i>BMJ Open</i> , 2013, 3, e003989. | 0.8 | 24 |
| 45 | A Tool to Predict Risk for Gastric Cancer in Patients With Peptic Ulcer Disease on the Basis of a Nationwide Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 287-293.e1. | 2.4 | 24 |
| 46 | Treatment of <i>Helicobacter pylori</i> infection: Where are we now?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1918-1926. | 1.4 | 24 |
| 47 | RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. <i>Journal of Gastroenterology</i> , 2008, 43, 115-123. | 2.3 | 23 |
| 48 | Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for <i>Helicobacter pylori</i> eradication: analysis of five randomized trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3481-3489. | 1.3 | 23 |
| 49 | Comparison of DNA stabilizers and storage conditions on preserving fecal microbiota profiles. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1791-1798. | 0.8 | 23 |
| 50 | <i>Helicobacter pylori</i> infection is not associated with increased risk of colorectal polyps in Taiwanese. <i>International Journal of Cancer</i> , 2006, 119, 1999-2000. | 2.3 | 21 |
| 51 | IL-1B-511 C>T Polymorphism is Associated with Increased Host Susceptibility to <i>Helicobacter pylori</i> Infection in Chinese. <i>Helicobacter</i> , 2007, 12, 142-149. | 1.6 | 21 |
| 52 | First-line antibiotic therapy in <i>Helicobacter pylori</i> -negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Scientific Reports</i> , 2017, 7, 14333. | 1.6 | 21 |
| 53 | Expressions of the CagA protein and CagA-signaling molecules predict <i>Helicobacter pylori</i> dependence of early-stage gastric DLBCL. <i>Blood</i> , 2017, 129, 188-198. | 0.6 | 20 |
| 54 | 14-day sequential therapy versus 10-day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of <i>Helicobacter pylori</i> : a multicentre, non-inferiority, randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2510-2518. | 1.3 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. American Journal of Surgical Pathology, 2015, 39, 761-766. | 2.1 | 19 |
| 56 | Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1107-1116. | 1.4 | 19 |
| 57 | Development of bacterial transglycosylase inhibitors as new antibiotics: Moenomycin A treatment for drug-resistant Helicobacter pylori. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2412-2414. | 1.0 | 18 |
| 58 | The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota—a double-blind, placebo-controlled, randomized trial. Helicobacter, 2021, 26, e12857. | 1.6 | 18 |
| 59 | Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1219-1230. | 1.5 | 18 |
| 60 | Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancer. European Journal of Cancer, 2007, 43, 1276-1282. | 1.3 | 17 |
| 61 | Association between Helicobacter pylori infection and cognitive impairment in the elderly. Journal of the Formosan Medical Association, 2018, 117, 994-1002. | 0.8 | 17 |
| 62 | Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone. Therapeutic Advances in Gastroenterology, 2008, 1, 111-120. | 1.4 | 16 |
| 63 | Associations of Circulating Gut Hormone and Adipocytokine Levels with the Spectrum of Gastroesophageal Reflux Disease. PLoS ONE, 2015, 10, e0141410. | 1.1 | 16 |
| 64 | Screening for Colorectal Cancer in Average-Risk Chinese Population Using a Mixed Strategy with Sigmoidoscopy and Colonoscopy. Diseases of the Colon and Rectum, 2007, 50, 630-640. | 0.7 | 15 |
| 65 | Early risk stratification with simple clinical parameters for cirrhotic patients with acute upper gastrointestinal bleeding. American Journal of Emergency Medicine, 2010, 28, 884-890. | 0.7 | 15 |
| 66 | Glycated hemoglobin A1c is superior to fasting plasma glucose as an independent risk factor for colorectal neoplasia. Cancer Causes and Control, 2012, 23, 321-328. | 0.8 | 15 |
| 67 | Endoscopic submucosal dissection comparing with surgical resection in patients with early gastric cancer—A single center experience in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1750-1757. | 0.8 | 15 |
| 68 | Predictors of in-hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 344-351. | 1.4 | 14 |
| 69 | Can clinical features stratify use of endoscopy for dyspeptic patients with high background prevalence of upper gastrointestinal cancer?. Digestive and Liver Disease, 2012, 44, 218-223. | 0.4 | 13 |
| 70 | Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1626-1633. | 0.8 | 13 |
| 71 | Alteration of taste or smell as a predictor of COVID-19. Gut, 2021, 70, 806-807. | 6.1 | 13 |
| 72 | Treatment of Refractory Helicobacter pylori Infection-Tailored or Empirical Therapy. Gut and Liver, 2022, 16, 8-18. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Phaeohyphomycosis caused by <i>Exophiala</i> species in immunocompromised hosts. <i>Journal of the Formosan Medical Association</i> , 2002, 101, 523-6. | 0.8 | 13 |
| 74 | Serum vascular adhesion protein-1 predicts all-cause mortality and cancer-related mortality in subjects with colorectal cancer. <i>Clinica Chimica Acta</i> , 2014, 428, 51-56. | 0.5 | 12 |
| 75 | Emergency endoscopy for upper gastrointestinal bleeding in patients with coronary artery disease. <i>American Journal of Emergency Medicine</i> , 2009, 27, 802-809. | 0.7 | 11 |
| 76 | Current Status of the Spectrum and Therapeutics of <i>Helicobacter pylori</i> -Negative Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2022, 14, 1005. | 1.7 | 11 |
| 77 | The Impact of Gastric Atrophy on the Incidence of Diabetes. <i>Scientific Reports</i> , 2017, 7, 39777. | 1.6 | 10 |
| 78 | Application of <i>Helicobacter pylori</i> stool antigen test to survey the updated prevalence of <i>Helicobacter pylori</i> infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 233-240. | 1.4 | 9 |
| 79 | Changes of serum pepsinogen level and ABC classification after bariatric surgery. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1377-1385. | 0.8 | 9 |
| 80 | Bismuth salts with versus without acid suppression for <i>Helicobacter pylori</i> infection: A transmission electron microscope study. <i>Helicobacter</i> , 2021, 26, e12801. | 1.6 | 9 |
| 81 | Typhlitis associated with <i>Candida albicans</i> and <i>Pseudomonas aeruginosa</i> infection in a patient with herbal drug-induced neutropenia. <i>Annals of Hematology</i> , 2005, 84, 689-691. | 0.8 | 8 |
| 82 | Jejunojunal intussusception secondary to a jejunal lipoma in an adult. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 924-926. | 1.4 | 8 |
| 83 | Pandemic preparedness in Taiwan. <i>Nature Biotechnology</i> , 2020, 38, 932-933. | 9.4 | 8 |
| 84 | <i>Helicobacter Pylori</i> Infection in the Elderly. <i>International Journal of Gerontology</i> , 2008, 2, 145-153. | 0.7 | 7 |
| 85 | The passage of a colonic cast. <i>Lancet, The</i> , 2010, 375, 2099. | 6.3 | 7 |
| 86 | From germ theory to germ therapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 73-82. | 0.8 | 6 |
| 87 | A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. <i>Haematologica</i> , 2020, 105, e349-e354. | 1.7 | 5 |
| 88 | Comparison of the effect of clarithromycin triple therapy with or without <i>N</i> -acetylcysteine in the eradication of <i>Helicobacter pylori</i> : a randomized controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092730. | 1.4 | 5 |
| 89 | Effects of Vigiiis 101-LAB on a healthy population's gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study. <i>Heliyon</i> , 2020, 6, e04979. | 1.4 | 5 |
| 90 | Consensus of gastroesophageal reflux disease in Taiwan with endoscopy-based approach covered by National Health Insurance. <i>Advances in Digestive Medicine</i> , 2015, 2, 85-94. | 0.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Survey of the adherence to the consensus of gastroesophageal reflux disease before and after the implementation course. Journal of the Formosan Medical Association, 2018, 117, 440-449. | 0.8 | 3 |
| 92 | EUS features of duodenal lesions in Henoch-Schönlein purpura. Gastrointestinal Endoscopy, 2005, 62, 307. | 0.5 | 2 |
| 93 | Think Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks. Journal of the Formosan Medical Association, 2009, 108, 437-442. | 0.8 | 2 |
| 94 | A rare case of gastrocolic fistula caused by benign gastric ulcer. Advances in Digestive Medicine, 2018, 5, 142-144. | 0.1 | 2 |
| 95 | The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus. Helicobacter, 2018, 23, e12533. | 1.6 | 2 |
| 96 | Quadruple therapy for Helicobacter pylori infection – Authors' reply. Lancet, The, 2013, 381, 1459-1460. | 6.3 | 1 |
| 97 | IDDF2018-ABS-0076...Optimised 14-day levofloxacin sequential versus 10-day bismuth quadruple therapy containing high dose esomeprazole in the second-line and third-line treatment of helicobacter pylori – a multicenter randomised trial. , 2018, , . | | 1 |
| 98 | Comparative study of modified-release clarithromycin and immediate-release clarithromycin in the treatment of Helicobacter pylori-associated peptic ulcer disease. Hepato-Gastroenterology, 2006, 53, 792-6. | 0.5 | 1 |
| 99 | Age and distal colonic findings determine the yield of advanced proximal neoplasia in Chinese patients with rectal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1780-1785. | 1.4 | 0 |
| 100 | The Hybrid Screening Strategy Is Also Effective for Colorectal Cancer Screening in the Average-Risk Chinese Population. Gastroenterology, 2008, 134, 365. | 0.6 | 0 |
| 101 | A 61-year-old man with abdominal pain for 6 months: Figure 1. Gut, 2010, 59, 147-147. | 6.1 | 0 |
| 102 | P1-260: Relationship between helicobacter pylori infection and cognitive performance in elders. , 2015, 11, P454-P454. | | 0 |
| 103 | Prevention of Gastric Cancer by Helicobacter pylori Eradication: Current Evidence and Future Prospects. , 2016, , 181-202. | | 0 |
| 104 | Massive Left Pleural Effusion After Endoscopic Variceal Therapy. American Journal of Gastroenterology, 2016, 111, 455. | 0.2 | 0 |
| 105 | Reply to Kim J.S. and Kim B.-W.. American Journal of Gastroenterology, 2016, 111, 1497-1498. | 0.2 | 0 |
| 106 | Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 573-573. | 1.9 | 0 |
| 107 | Bismuth and Non-bismuth Quadruple Therapy for Helicobacter pylori Eradication: Time to Make the Switch in Clinical Practice?. Gastroenterology, 2017, 152, 301-302. | 0.6 | 0 |
| 108 | Optimization of Helicobacter pylori eradication therapies. Advances in Digestive Medicine, 2018, 5, 1-2. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----|-----------|
| 109 | IDDF2019-ABS-0213...Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after helicobacter pylori eradication- a multicentre randomised trial. , 2019, , . | | 0 |
| 110 | IDDF2019-ABS-0126...Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of helicobacter pylori -a multicenter randomized trial. , 2019, , . | | 0 |